Dean Capital Investments Management LLC cut its holdings in shares of Sanofi SA (NYSE:SNY) by 21.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 18,048 shares of the company’s stock after selling 5,064 shares during the period. Sanofi makes up about 0.5% of Dean Capital Investments Management LLC’s investment portfolio, making the stock its 20th largest holding. Dean Capital Investments Management LLC’s holdings in Sanofi were worth $836,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Ibex Wealth Advisors acquired a new position in shares of Sanofi during the second quarter worth approximately $25,000. Heritage Wealth Advisors raised its holdings in Sanofi by 141.2% during the second quarter. Heritage Wealth Advisors now owns 603 shares of the company’s stock worth $26,000 after purchasing an additional 353 shares in the last quarter. Bessemer Group Inc. raised its holdings in Sanofi by 292.4% during the second quarter. Bessemer Group Inc. now owns 671 shares of the company’s stock worth $29,000 after purchasing an additional 500 shares in the last quarter. Prestige Wealth Management Group LLC bought a new stake in Sanofi during the second quarter worth approximately $37,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new stake in Sanofi during the third quarter worth approximately $37,000. Institutional investors and hedge funds own 7.04% of the company’s stock.
NYSE:SNY traded up $0.09 during trading hours on Tuesday, hitting $45.95. 52,702 shares of the stock traded hands, compared to its average volume of 1,307,250. The firm has a 50 day moving average price of $45.83 and a 200 day moving average price of $43.41. The company has a current ratio of 1.22, a quick ratio of 0.85 and a debt-to-equity ratio of 0.40. Sanofi SA has a fifty-two week low of $40.00 and a fifty-two week high of $47.47. The firm has a market cap of $114.86 billion, a price-to-earnings ratio of 14.68, a PEG ratio of 2.41 and a beta of 0.67.
SNY has been the topic of several recent analyst reports. Zacks Investment Research raised Sanofi from a “hold” rating to a “buy” rating and set a $47.00 target price on the stock in a report on Thursday, August 29th. Guggenheim raised Sanofi from a “neutral” rating to a “buy” rating in a report on Monday, September 23rd. Sanford C. Bernstein initiated coverage on Sanofi in a report on Tuesday, September 3rd. They set an “outperform” rating and a $52.00 target price on the stock. Morgan Stanley raised Sanofi from an “equal” rating to a “weight” rating in a report on Friday, September 20th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Sanofi in a report on Thursday, August 29th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $49.50.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Read More: What is basic economics?
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.